Series A financing co-led by Westlake Village BioPartners and Versant Ventures Company advancing systemically delivered, skeletal and cardiac muscle targeted, liver de-targeted capsid and cargo technology platforms Initial pipeline addressing myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy Company grants Astellas Pharma Inc. exclusive license to KT430 to treat X-linked […]
